Survey on Epidemiology of Hypoparathyroidism in France

Assessment of the biology at inclusion will describe the evolution of the included population from diagnosis to now (inclusion)

Number of patients with at least one anomaly at biology (calcemia in mM, calciuria in mmol/j, parathormone in pg/ml, creatininemia in µM, phosphatemia in mM, vitamin D in nmol/l \& magnesemia in mM) at inclusion

Time frame: At inclusion (under treatment): through study completion, about 2 years

Assessment of the management at inclusion will describe treatment and complications at inclusion

Number of patients with clinical outcomes (complications such as cataract, nephrolithiasis, nephrocalcinosis, and others) and their management at inclusion

Time frame: At inclusion (under treatment): through study completion, about 2 years

Assessment of the biology (calcemia, calciuria, parathormone, creatininemia, phosphatemia & magnesemia) at diagnosis and drug therapy at inclusion will describe population

Number of patients with at least one anomaly at biology (calcemia in mM, calciuria in mmol/j, parathormone in pg/ml, creatininemia in µM, phosphatemia in mM, vitamin D in nmol/l \& magnesemia in mM) at diagnosis

Time frame: Through study completion, about 2 years